Clifton Mo, MD

In a video interview, Clifton C. Mo, MD, Director of Autologous Stem Cell Transplantation for Multiple Myeloma at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses the importance of “listening to each other,” remaining aware of clinical trials with promising clinical agents and being conscious of feedback from real-world settings.

In a video interview, Clifton C. Mo, MD, Director of Autologous Stem Cell Transplantation for Multiple Myeloma at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses how the COVID-19 pandemic has impacted the field at the initial surge.

In a video interview, Clifton C. Mo, MD, Director of Autologous Stem Cell Transplantation for Multiple Myeloma at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses what the exciting response rates seen with CAR-T mean for clinicians and patients.

In a video interview,  Clifton C. Mo, MD,  Director of Autologous Stem Cell Transplantation for Multiple Myeloma at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses what is in the pipeline for multiple myeloma.

Healio spoke with Clifton C. Mo, MD, Director of Autologous Stem Cell Transplantation for Multiple Myeloma at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School about the importance of being aware of feedback from real-world settings.